Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04921904 · ClinicalTrials.gov registry record · Phase 1

Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca

A Phase 1 study of Metastatic Gastroesophageal Junction Adenocarcinoma and Metastatic Esophageal Adenocarcinoma, sponsored by Baylor Research Institute.

Active
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT04921904: Active Phase 1 study of Metastatic Gastroesophageal Junction Adenocarcinoma and Metastatic Esophageal Adenocarcinoma, sponsored by Baylor Research Institute.

NCT04921904 is a Phase 1 study of Metastatic Gastroesophageal Junction Adenocarcinoma and Metastatic Esophageal Adenocarcinoma that is active but no longer recruiting, run by Baylor Research Institute. The registered enrollment target is 8 participants, below the 41-participant average among 8 other Metastatic Gastroesophageal Junction Adenocarcinoma trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04921904, a Phase 1 study of Metastatic Gastroesophageal Junction Adenocarcinoma and Metastatic Esophageal Adenocarcinoma, is active but no longer recruiting, sponsored by Baylor Research Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

CDK4/6 and Cyclin D1 are significantly expressed in approximately 80% of esophageal and gastroesophageal junction tumors suggesting that CDK4/6 inhibition may be a successful strategy in these chemotherapy and immunotherapy resistant diseases.

Conditions Studied

Metastatic Gastroesophageal Junction Adenocarcinoma Metastatic Esophageal Adenocarcinoma

Interventions

  • DRUG Abemaciclib
  • DRUG Ramucirumab

Study Locations (1)

Texas

  • Baylor University Medical Center, Charles A Sammons Cancer Center - Dallas

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2021-06-11
Est. Completion 2026-06
Phase Phase 1
Baylor Research Institute

180 total trials

What the registry record for NCT04921904 still lists

NCT04921904 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 41-participant average among 8 other Metastatic Gastroesophageal Junction Adenocarcinoma trials with a reported enrollment target (80% lower).

The record links to 2 conditions, with Metastatic Gastroesophageal Junction Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Abemaciclib is the first listed.

NCT04921904 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT04921904 about?

NCT04921904 is a clinical study titled "Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca". CDK4/6 and Cyclin D1 are significantly expressed in approximately 80% of esophageal and gastroesophageal junction tumors suggesting that CDK4/6 inhibition may be a successful strategy in these chemotherapy and immunotherapy resistant diseases.

What is the current status of trial NCT04921904?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-06-11. Estimated completion is 2026-06.

What conditions does trial NCT04921904 study?

This clinical trial studies the following conditions: Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Adenocarcinoma.

What interventions are being tested in trial NCT04921904?

The interventions under investigation include: Abemaciclib (DRUG), Ramucirumab (DRUG).

Who is sponsoring clinical trial NCT04921904?

This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04921904 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Gastroesophageal Junction Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04921904's enrollment target sits among peer trials

8 9th of 8 the lowest of 8 other Metastatic Gastroesophageal Junction Adenocarcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Gastroesophageal Junction Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04921904, the US trial registry maintained by the National Library of Medicine. NCT04921904 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.